Eli Lilly and Company (NYSE:LLY) Shares Sold by First Citizens Financial Corp

First Citizens Financial Corp lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,608 shares of the company’s stock after selling 58 shares during the quarter. Eli Lilly and Company makes up 1.7% of First Citizens Financial Corp’s holdings, making the stock its 18th biggest position. First Citizens Financial Corp’s holdings in Eli Lilly and Company were worth $3,196,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Capital Planning LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth $262,000. CHURCHILL MANAGEMENT Corp acquired a new position in Eli Lilly and Company during the first quarter worth approximately $6,916,000. M&G Plc purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $8,896,000. HighPoint Advisor Group LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $9,878,000. Finally, Leo Wealth LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $3,355,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.7 %

LLY opened at $885.15 on Friday. The business’s 50-day moving average price is $898.50 and its 200-day moving average price is $846.49. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $523.63 and a 12 month high of $972.53. The company has a market cap of $841.25 billion, a P/E ratio of 130.36, a P/E/G ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, equities analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 93,593 shares of the stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $918.64, for a total transaction of $85,978,273.52. Following the sale, the insider now directly owns 97,153,810 shares of the company’s stock, valued at approximately $89,249,376,018.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on LLY shares. Berenberg Bank raised their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research report on Thursday. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Finally, Barclays lifted their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.